KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Free Cash Flow: 2010-2025

Historic Free Cash Flow for Pacira BioSciences (PCRX) over the last 15 years, with Sep 2025 value amounting to $57.0 million.

  • Pacira BioSciences' Free Cash Flow rose 14.32% to $57.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.2 million, marking a year-over-year decrease of 35.82%. This contributed to the annual value of $178.8 million for FY2024, which is 28.15% up from last year.
  • Per Pacira BioSciences' latest filing, its Free Cash Flow stood at $57.0 million for Q3 2025, which was up 511.53% from $9.3 million recorded in Q2 2025.
  • Pacira BioSciences' 5-year Free Cash Flow high stood at $57.0 million for Q3 2025, and its period low was -$992,000 during Q1 2021.
  • Over the past 3 years, Pacira BioSciences' median Free Cash Flow value was $41.0 million (recorded in 2023), while the average stood at $37.4 million.
  • Per our database at Business Quant, Pacira BioSciences' Free Cash Flow crashed by 92.25% in 2021 and then spiked by 2,429.54% in 2022.
  • Pacira BioSciences' Free Cash Flow (Quarterly) stood at $14.0 million in 2021, then soared by 160.13% to $36.5 million in 2022, then rose by 25.29% to $45.8 million in 2023, then plummeted by 32.26% to $31.0 million in 2024, then increased by 14.32% to $57.0 million in 2025.
  • Its Free Cash Flow was $57.0 million in Q3 2025, compared to $9.3 million in Q2 2025 and $26.9 million in Q1 2025.